Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus PT from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned an average rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.67.

IMUX has been the subject of a number of research reports. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. HC Wainwright initiated coverage on Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 target price for the company. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Monday.

Hedge Funds Weigh In On Immunic

A number of large investors have recently modified their holdings of the business. HB Wealth Management LLC acquired a new position in shares of Immunic during the 4th quarter worth about $81,000. Virtu Financial LLC acquired a new position in shares of Immunic during the 3rd quarter worth about $50,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. State Street Corp lifted its stake in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Trading Down 1.3 %

IMUX stock opened at $0.94 on Thursday. The stock has a 50-day moving average price of $1.05 and a two-hundred day moving average price of $1.27. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.